Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study

Ahmed, Nadeem; Prior, James A.; Chen, Ying; Hayward, Richard; Mallen, Christian; Hider, Samantha L.

doi:10.1007/s10067-016-3362-2

Cited by 34 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study showed that hypertension was a common comorbidity in the AS population, and the overall prevalence of hypertension was 22.4% in AS patients. A previous study also showed that the prevalence of hypertension in patients with AS was more frequent compared with matched cohorts [44]. In our study, the prevalence of hypertension was significantly higher in male CKD patients compared with female CKD patients (37.8% vs 17.1%, p = 0.025) and multiple regression analysis showed that hypertension is a risk factor for CKD only for male patients.…”

Section: Discussionsupporting

confidence: 74%

Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study

Zhuang

Yang

et al. 2019

BMC Nephrol

View full text Add to dashboard Cite

Background: Ankylosing spondylitis (AS) is a well-known male-predominant inflammatory disease. This study aimed to assess the gender disparity in chronic kidney disease (CKD) in AS patients in China. Methods: AS patients were retrospectively studied at Peking Union Medical College hospital between January 2002 and June 2018. Results: Among 616 patients with AS, 154 (25.0%) patients had CKD (age, 41.8 ± 14.2 years; male:female, 3.2:1). Overall, 80 (13.0%) patients had only microscopic hematuria, 62 (10.1%) had proteinuria with or without hematuria, and 33 (5.4%) exhibited a reduced estimated glomerular filtration rate (eGFR, ≤60 mL/min/1.73 m 2). Male CKD patients had more frequent proteinuria (p < 0.01), less microscopic hematuria only (p < 0.01), and lower eGFR (p = 0.04) compared with females. CKD was independently associated with hyperuricemia and total cholesterol in females, and with hyperuricemia, hypertension, and serum albumin in males. After follow-up for 1-7 years, five patients required renal replacement therapy including two patients who were already at stage 5 CKD when enrolled and three patients whose creatinine doubled. One patient died in the male group. No patients in the female group showed progression of renal dysfunction. Conclusions: CKD is a common comorbidity in patients with AS. Male patients are more likely to develop severe manifestations compared with female patients. Hyperuricemia was a strong independent risk factor for CKD in both genders, while hypertension and low serum albumin were risk factors for CKD only in males.

show abstract

Section: Discussionsupporting

confidence: 74%

Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study

Zhuang

Yang

et al. 2019

BMC Nephrol

View full text Add to dashboard Cite

show abstract

“…A total of 36 studies reported prevalence of individual comorbidities with a combined sample size of 119 427 patients [ 1 , 2 , 5 , 11 , 13 , 15–45 ]. All studies reported one or more diseases of the cardiovascular system; 21 studies included a gastrointestinal or hepatic disorder; 21 included cancers; 18 pulmonary disorders; 16 mental health disorders (anxiety or depression).…”

Section: Resultsmentioning

confidence: 99%

“…Eleven studies compared comorbidities between axSpA and control groups [ 5 , 13 , 15–18 , 20 , 26 , 36 , 37 , 41 ]. Six studies selected controls without AS or inflammatory rheumatic diseases, while five others did not specify or selected from the whole population.…”

Section: Resultsmentioning

confidence: 99%

Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Objectives Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on axSpA outcomes. Methods We systematically searched Medline, PubMed, Scopus and Web of Science using a predefined protocol in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We excluded studies of only one comorbid condition or a few closely related diseases within one organ system. Where possible, meta-analysis was performed using random-effects models. Results A total of 40 studies were included for analysis. 36 studies reported prevalence of comorbidities, amounting to a combined sample size of 119 427 patients. The number of comorbidities studied ranged from 3 to 43. The most prevalent individual comorbidities were hypertension (pooled prevalence 23%), hyperlipidaemia (17%) and obesity (14%). Eleven studies consistently showed higher prevalence of comorbidities in axSpA than controls, particularly large differences were seen for depression [pooled odds ratio (OR) 1.80] and heart failure (OR 1.84). Comorbidities (total number of and individual conditions) were also associated with axSpA disease activity, functional impairment, quality of life, work productivity and mortality. Conclusions Comorbidities are common in axSpA, particularly cardiovascular diseases and risk factors. Most comorbidities were more prevalent in axSpA patients than in control populations. Overall comorbidity burden, and many individual conditions, were associated with axSpA outcomes including worse disease severity, work productivity and mortality.

show abstract

“…Hypertension is one of the most prevalent CVRF, estimated to account for 50% of all strokes and IHD events in the general population ( 43 ). Several studies have reported an increased prevalence of hypertension in SpA patients, compared with controls both in axial and peripheral forms of SpA (including PsA) ( 5 , 37 , 44 – 46 ): a recent cross-sectional international study including 4,000 SpA patients worldwide ( 5 ) reported hypertension to be the most frequent CVFR in this population, with a prevalence to 33.5% (95% CI = 32.0–35.0%) patients; another study ( 45 ) reported a substantially higher prevalence of hypertension in patients with r-axSpA compared with the general population in the Netherlands (41 vs. 31%, respectively).…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Comorbidities in Spondyloarthritis

Moltó

Nikiphorou

2018

Front. Med.

View full text Add to dashboard Cite

Comorbidities in spondyloarthritis (SpA) add to the burden of disease by contributing to disease activity, functional and work disability, and mortality. Thus, awareness of comorbidities in SpA is crucial to improve their screening and management and to ultimately improve outcomes in those affected. Osteoporosis has been reported to be the most prevalent comorbidity in SpA, and its risk is increased in these patients, compared with the general population; the risk of vertebral fractures requires further evaluation. Cardiovascular risk is also increased in this population, both due to an increase of the traditional cardiovascular risk factors in these patients, but also due to the presence of inflammation. The role of non-steroidal anti-inflammatory drugs in this increased risk needs further elucidation, but there is consensus on the need to encourage smoking cessation and to perform periodic evaluation of cardiovascular risk in these patients, particularly in the case of change in treatment course. Concerning the risk of cancer, no increased risk inherent to SpA seems to exist. However, an increased neoplastic risk can occur due to SpA treatments, e.g., P-UVA. Data are sparse on the risk of infections compared with rheumatoid arthritis, but there appears to be no risk in the absence of TNF-inhibitor exposure. Regardless of which comorbidity, a gap exists between recommendations for their management and actual implementation in clinical practice, suggesting that there is still a need for improvement in this area. Systematic screening for these comorbidities should improve both short- and long-term outcomes in SpA patients.

show abstract

Prevalence of cardiovascular-related comorbidity in ankylosing spondylitis, psoriatic arthritis and psoriasis in primary care: a matched retrospective cohort study

Cited by 34 publications

References 24 publications

Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study

Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study

Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis

Comorbidities in Spondyloarthritis

Contact Info

Product

Resources

About